Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

ACTIVE NOT RECRUITING

NCT06282159

PHASE2

A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)

Sponsor: Dianthus Therapeutics

View on ClinicalTrials.gov

Summary

The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with generalized myasthenia gravis (gMG).

Official title: A Phase 2, Randomized, Blinded, Placebo-Controlled, Study to Evaluate Safety, Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2024-02-23

Completion Date

2027-08

Last Updated

2025-10-07

Healthy Volunteers

Conditions

Myasthenia Gravis, Generalized

Interventions

DRUG

DNTH103

Day 1: IV loading dose Week 1 to Week 11: DNTH103 administered SC every 2 weeks

DRUG

Placebo

Day 1: IV infusion of placebo Week 1 to Week 11: placebo administered SC every 2 weeks

Inclusion Criteria: 1. Must have given written informed consent before any study-related activities are carried out. 2. Adult males and females, 18 to 75 years of age (inclusive) at Screening. 3. Weight range between 40-120 kg at Screening. 4. Diagnosis of gMG by the following tests: Acetylcholine receptor antibody (AChR Ab) positive, and One of the following: i. History of abnormal neuromuscular transmission test; ii. History of positive anticholinesterase test; iii. Clinical response to acetylcholinesterase inhibitors. 5. Myasthenia Gravis Foundation of America (MGFA) Class II-Iva 6. Myasthenia Gravis Activities of Daily Living (MG-ADL) score of 6 or more 7. Vaccination against N. meningitidis with the quadrivalent meningococcal vaccine, and where available, meningococcal serotype B vaccine within 3 years prior to, or at the time of, initiating study drug. 8. Female participants must: Be of non-childbearing potential, or if of childbearing potential, must agree not to donate ova, not to attempt to become pregnant and, if engaging in sexual intercourse with a male partner, must agree to use a highly effective method of contraception. 9. Male participants must be surgically sterile for at least 90 days prior to screening or agree not to donate sperm Exclusion Criteria: 1. History or presence of significant medical/surgical condition including any acute illness or major surgery considered to be clinically significant 2. Prior history (at any time) of N. meningitidis infection. 3. Positive test results for active human immunodeficiency virus (HIV-1 or HIV-2), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibodies during Screening. 4. Any thymic surgery/biopsy within 1 year of Screening. 5. Any known or untreated thymoma. 6. Any history of thymic carcinoma or thymic malignancy. 7. Concurrent or previous use of the following medication within the time periods specified below. 1. Rituximab within 6 months (180 days) prior to randomization (Day 1); 2. Intravenous immunoglobulin (IVIg) and plasma exchange (PLEX) within 4 weeks (28 days) prior to randomization (Day 1). 8. Participation in another clinical study of an investigational drug within 90 days or 5 half-lives of the investigational agent.

Locations (56)

Clinical Study Site

Phoenix, Arizona, United States

Clinical Study Site

Irvine, California, United States

Clinical Study Site

Stamford, Connecticut, United States

Clinical Study Site

Boca Raton, Florida, United States

Clinical Study Site

Bradenton, Florida, United States

Clinical Study Site

Maitland, Florida, United States

Clincal Study Site

Tampa, Florida, United States

Clinical Study Site

O'Fallon, Illinois, United States

Clinical Study Site

Kansas City, Kansas, United States

Clinical Study Site

Lexington, Kentucky, United States

Clinical Study Site

Boston, Massachusetts, United States

Clinical Study Site

East Lansing, Michigan, United States

Clinical Study Site

Columbia, Missouri, United States

Clinical Study Site

Cincinnati, Ohio, United States

Clinical Study Site

Columbus, Ohio, United States

Clinical Study Site

Dallas, Texas, United States

Clinical Study Site

Dallas, Texas, United States

Clinical Study Site #2

Houston, Texas, United States

Clinical Study Site

Houston, Texas, United States

Clinical Study Site

Lubbock, Texas, United States

Clinical Study Site

Richmond, Virginia, United States

Clinical Study Site

San Miguel de Tucumán, Tucumán Province, Argentina

Clinical Study Site

Buenos Aires, Argentina

Clinical Study Site

Buenos Aires, Argentina

Clinical Study Site

Buenos Aires, Argentina

Clinical Study Site

Córdoba, Argentina

Clinical Study Site

Rosario, Argentina

Clinical Study Site

London, Ontario, Canada

Clinical Study Site

Ostrava, Czechia

Clinical Study Site

Copenhagen, Denmark

Clinical Study Site

Bordeaux, France

Clinical Study Site

Nice, France

Clinical Study Site

Strasbourg, France

Clinical Study Site

Haifa, Israel

Clinical Study Site

Ramat Gan, Israel

Clinical Study Site

Safed, Israel

Clinical Study Site

Milan, Italy

Clinical Study Site

Naples, Italy

Clinical Study Site

Pisa, Italy

Clinical Study Site

Rome, Italy

Clinical Study Site

Rome, Italy

Clinical Study Site

Amsterdam, Netherlands

Clinical Study Site

Skopje, North Macedonia

Clinical Study Site

Bergen, Norway

Clinical Study Site

Bydgoszcz, Poland

Clinical Study Site

Katowice, Poland

Clinical Study Site

Krakow, Poland

Clinical Study Site

Krakow, Poland

Clinical Study Site

Lublin, Poland

Clinical Study Site

Warsaw, Poland

Clinical Study Site

Warsaw, Poland

Clinical Study Site

Belgrade, Serbia

Clinical Study Site

Kragujevac, Serbia

Clinical Study Site

Niš, Serbia

Clinical Study Site

Novi Sad, Serbia

Clinical Study Site

Malmo, Sweden

Clinical Research Directory

A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)

Summary

Key Details

Conditions

Interventions

Eligibility Criteria

Locations (56)